Provided by Tiger Fintech (Singapore) Pte. Ltd.

BridgeBio Pharma, Inc.

40.00
-1.1400-2.77%
Volume:987.53K
Turnover:39.94M
Market Cap:7.60B
PE:-11.31
High:41.12
Open:41.07
Low:39.91
Close:41.14
Loading ...

BridgeBio Pharma Price Target Maintained With a $49.00/Share by HC Wainwright & Co.

Dow Jones
·
13 Feb

BridgeBio price target raised to $49 from $48 at Scotiabank

TIPRANKS
·
12 Feb

Scotiabank Remains a Buy on BridgeBio Pharma (BBIO)

TIPRANKS
·
12 Feb

European Equities Close Higher in Tuesday Trading; EC Vows to Reciprocate US Steel, Aluminum Tariffs

MT Newswires Live
·
12 Feb

BridgeBio Pharma Says Beyonttra Gets EU Marketing Approval for Transthyretin Amyloidosis

MT Newswires Live
·
11 Feb

BridgeBio announces EC marketing authorization for BETONTTRA

TIPRANKS
·
11 Feb

BridgeBio Pharma Inc - Bayer to Launch Acoramidis in First Half of 2025

THOMSON REUTERS
·
11 Feb

Beyonttra™ (Acoramidis), the First Near Complete Ttr Stabilizer (≥90%), Approved by the European Commission to Treat Attr-Cm

THOMSON REUTERS
·
11 Feb

BridgeBio Pharma Inc - to Receive $75 Million Milestone Payment From Bayer

THOMSON REUTERS
·
11 Feb

Why BridgeBio Pharma, Inc. (BBIO) Is Among the Best Healthcare Stocks To Buy According to Analysts

Insider Monkey
·
08 Feb

DHT, Evolve Technologies, and More Stocks See Action From Activist Investors -- Barrons.com

Dow Jones
·
08 Feb

Why BridgeBio Pharma Inc. (BBIO) Crashed on Monday

Insider Monkey
·
04 Feb

Brian's Big Idea: Healthcare Stocks

Zacks
·
30 Jan

Is BridgeBio Pharma, Inc. (BBIO) the Unstoppable Stock to Buy in 2025?

Insider Monkey
·
30 Jan

Why BridgeBio Pharma (BBIO) Is Skyrocketing Now

Insider Monkey
·
26 Jan

U.S. Weekly Review: Stock Market Rises On Tame Inflation, Bank Earnings

Investor’s Business Daily
·
18 Jan

Why BridgeBio Pharma (BBIO) Led the Monday Upsurge?

Insider Monkey
·
14 Jan

Oppenheimer Sticks to Its Hold Rating for BridgeBio Pharma (BBIO)

TIPRANKS
·
14 Jan

Strength Seen in BridgeBio Pharma (BBIO): Can Its 16.0% Jump Turn into More Strength?

Zacks
·
14 Jan

BRIEF-Bridgebio Pharma Says Got $500 Mln Upon Acoramidis U.S. Food And Drug Administration Approval

Reuters
·
14 Jan